MedTrace Logo

Hypertension Registry of "Hypertension Prevention and Control Initiative in China"

NCT04289701 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200000

Last updated 2020-02-28

No results posted yet for this study

Summary

Hypertension is the leading preventable risk factor of cardiovascular disease globally and in China. Unparalleled to remarkable increase of hypertension burden in China, blood pressure(BP) control is inadequate. A political public health project, "Hypertension Prevention and Control Initiative in China(Chronic Disease Demonstration District Construction)", was initiated in October 2019 for explore a feasible and reproducible archetype for hypertension management and to improve the registration, management, treatment and control rates of hypertension in China. The project is designed to consecutively implement health service strategies in 40 pilot counties covering 31 provinces and around 200,000 hypertension patients in mainland China, via the National Medical Alliance for Hypertension(NMAH). The Hypertension Registry study aims to registry, follow up and observe the clinical features, treatment, blood pressure control and outcomes of all hypertension patients managed in the "Hypertension Prevention and Control Initiative in China" project.

Conditions

Interventions

OTHER

Health Services for Systematic Hypertension Management

The systematic hypertension management health services from the "Hypertension prevention and control initiative in China" project. Main services are as follows: 1. Healthcare provider training and patient education. 2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation. 3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform. 4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs. 5. Outcome and performance evaluation quarterly. 6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients. 7. Certification for "Honorary Hypertension Centers" at county levels and establishment for hypertension clinics at primary care centers.

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    lead OTHER

Principal Investigators

  • Jun Cai, MD,PhD · Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2022-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04289701 on ClinicalTrials.gov